ARTICLE | Clinical News
LJPC-501: SPA received
March 9, 2015 7:00 AM UTC
La Jolla said it received an SPA from FDA for a double-blind, placebo-controlled, U.S. Phase III trial of LJPC-501 in about 315 patients. La Jolla plans to begin the trial this quarter. ...